Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enarodustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 known ✓ | Q9GZT9 | 17/20 | 0.64 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.53 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enarodustat SCHEMBL21403279 | 0.99 | EGLN1 (0.63) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| Enarodustat SCHEMBL1481939 | 0.99 | EGLN1 (0.65) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| SCHEMBL1483208 | 0.94 | EGLN1 (0.59) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| SCHEMBL12828326 | 0.91 | EGLN1 (0.55) | EGLN1BBOX1ASPHKDM8 | |
| Enarodustat SCHEMBL21403278 | 0.91 | EGLN1 (0.53) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| SCHEMBL12828377 | 0.91 | EGLN1 (0.53) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| Hydrochloric Acid SCHEMBL1484087 | 0.90 | EGLN1 (0.55) | EGLN1BBOX1ASPHKDM8 | |
| Hydrochloric Acid SCHEMBL1482494 | 0.90 | EGLN1 (0.54) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| SCHEMBL12828569 | 0.88 | EGLN1 (0.51) | EGLN1BBOX1ASPHKDM8EGLN3 | |
| SCHEMBL12828131 | 0.87 | EGLN1 (0.49) | EGLN1BBOX1ASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724570-A1 | SMALL MOLECULE BASED METHOD OF MODIFYING T CELLS | Agency for Science, Technology and Research (SG) | 2026-04-15 | — | — | EP | claimed |
| EP-4637791-A1 | SEVUPARIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | Modus Therapeutics AB (SE) | 2025-10-29 | — | — | EP | claimed |
| US-12337027-B2 | Methods and compositions relating to lung repair | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-24 | — | — | US | claimed |
| US-20250171821-A1 | HIF-1 ACTIVATORS AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-05-29 | — | — | US | claimed |
| WO-2025087208-A1 | USE OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) IN RARE ANEMIA | 杭州安道药业有限公司 | 2025-05-01 | — | — | WO | claimed |
| WO-2025087207-A1 | LONG-ACTING ORAL PHARMACEUTICAL COMPRISING HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR AND USE THEREOF | 杭州安道药业有限公司 | 2025-05-01 | — | — | WO | claimed |
| CN-119868549-A | Long-acting oral medicine containing hypoxia inducible factor-prolyl hydroxylase inhibitor and application thereof | 杭州安道药业有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119868550-A | Use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) in rare anemias | 杭州安道药业有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| WO-2025029611-A1 | THERAPIES FOR DISEASES OF COPPER METABOLISM | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2025-02-06 | — | — | WO | claimed |
| US-20230201359-A1 | MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR DELIVERING THERAPEUTIC AGENTS TO HEART | ACADEMIA SINICA (TW) | 2023-06-29 | — | — | US | claimed |
| WO-2023107977-A1 | METHODS AND COMPOSITIONS FOR TREATING AIRWAY INFLAMMATION | THE UNIVERSITY OF CHICAGO (US) | 2023-06-15 | — | — | WO | claimed |
| US-20230101768-A1 | METHOD TO TREAT MANGANESE TOXICITY AND MANGANESE-INDUCED PARKINSONISM IN HUMANS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-30 | — | — | US | claimed |
| EP-4142721-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | Bioage Labs, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2023027098-A1 | ANTI–HEPATITIS B VIRUS AGENT AND USE FOR SAME | 国立大学法人北海道大学 | 2023-03-02 | — | — | WO | claimed |
| EP-4138825-A1 | TREATMENT OF VIRAL INFECTIONS, OF ORGAN INJURY, AND OF RELATED CONDITIONS USING A HIF PROLYL HYDROXYLASE INHIBITOR OR A HIF-ALPHA STABILIZER | Akebia Therapeutics Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| CN-115246830-A | Solid form of acid and preparation method thereof | 广东东阳光药业有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-115197209-A | Crystal form of acid and preparation method thereof | 广东东阳光药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-115197210-A | Crystal form of acid and preparation method thereof | 广东东阳光药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| WO-2022150623-A1 | COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF ANEMIA | AKEBIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | EGLN1 503/4885BBOX1 3304/4885ASPH 3482/4885 |
| US-20230101768-A1 | METHOD TO TREAT MANGANESE TOXICITY AND MANGANESE-INDUCED PARKINSONISM IN HUMANS | HIF1AN, EGLN3, HIF1A | EGLN1 14/4885BBOX1 1102/4885ASPH 38/4885 |
| US-20230201359-A1 | MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR DELIVERING THERAPEUTIC AGENTS TO HEART | FABP3, CD14, FABP1 | EGLN1 3840/4885BBOX1 4498/4885ASPH 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.